Literature DB >> 17937643

Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations.

Timothy H Mathew1, David W Johnson, Graham R D Jones.   

Abstract

Since publication of the Australasian Creatinine Consensus Working Group's position statement in 2005, most Australasian laboratories now automatically report an estimated glomerular filtration rate (eGFR) (based on the Modification of Diet in Renal Disease [MDRD] formula) with results of serum creatinine tests in adults. Anecdotal evidence suggests that automatic reporting of eGFR helps to identify asymptomatic kidney dysfunction at an earlier stage and to develop rational and appropriate management plans. Changes to the measurement and calibration of serum creatinine assays and issues regarding implementation of eGFR in clinical practice led the Australasian Creatinine Consensus Working Group to reconvene in 2007. The recommendations contained here build on the original 2005 position statement and consolidate the role of eGFR in clinical practice. The Working Group recommends that the eGFR upper reporting limit be extended to 90 mL/min/1.73 m2, with eGFR values above this amount being reported as "> 90 mL/min/1.73 m2", rather than as a precise figure. The Working Group has concluded that it is currently premature to recommend age-related decision points for eGFR. However, it is appropriate to advise medical practitioners that, in people aged >/= 70 years, an eGFR in the range 45-59 mL/min/1.73 m2, if stable over time and unaccompanied by other evidence of kidney damage, may be interpreted as consistent with a typical eGFR for this age group and is unlikely to be associated with chronic kidney disease-related complications. Pending publication of validation studies, the Working Group recommends that Australasian laboratories continue to automatically report eGFR in Aboriginal and Torres Strait Islander peoples and other ethnic groups. The Working Group supports the use of eGFR to assist drug dosing decision making in general practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937643     DOI: 10.5694/j.1326-5377.2007.tb01357.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  29 in total

1.  Estimating renal function for drug dosing decisions.

Authors:  Graham Rd Jones
Journal:  Clin Biochem Rev       Date:  2011-05

2.  Chronic kidney disease - an exemplar for collaboration between the clinic and the laboratory.

Authors:  Timothy Mathew
Journal:  Clin Biochem Rev       Date:  2011-05

3.  Methods of Estimating GFR - Different Equations Including CKD-EPI.

Authors:  Christopher M Florkowski; Janice Sc Chew-Harris
Journal:  Clin Biochem Rev       Date:  2011-05

4.  Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings.

Authors:  Aarati Khanal; Gregory M Peterson; Ronald L Castelino; Matthew D Jose
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

5.  An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia and New Zealand Dialysis and Transplantation Registry).

Authors:  Annie-Claire Nadeau-Fredette; Carmel M Hawley; Elaine M Pascoe; Christopher T Chan; Philip A Clayton; Kevan R Polkinghorne; Neil Boudville; Martine Leblanc; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-11       Impact factor: 8.237

6.  Application of the stockholm hierarchy to defining the quality of reference intervals and clinical decision limits.

Authors:  Ken Sikaris
Journal:  Clin Biochem Rev       Date:  2012-11

7.  Point-of-Care Testing and Creatinine Measurement.

Authors:  Mark Ds Shephard
Journal:  Clin Biochem Rev       Date:  2011-05

8.  Study Protocol--accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR study.

Authors:  Louise J Maple-Brown; Paul D Lawton; Jaquelyne T Hughes; Suresh K Sharma; Graham Rd Jones; Andrew G Ellis; Wendy Hoy; Alan Cass; Richard J Macisaac; Ashim K Sinha; Mark Ab Thomas; Leonard S Piers; Leigh C Ward; Katrina Drabsch; Sianna Panagiotopoulos; Robyn McDermott; Kevin Warr; Sajiv Cherian; Alex Brown; George Jerums; Kerin O'Dea
Journal:  BMC Public Health       Date:  2010-02-19       Impact factor: 3.295

9.  Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy.

Authors:  Laurence Viollet; Susan Gailey; David J Thornton; Neil R Friedman; Kevin M Flanigan; John D Mahan; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

10.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.